SUNPHARMA.BOSUNPHARMA.BO
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-13.13%
↓ 689% below average
Average (39q)
2.23%
Historical baseline
Range
High:43.90%
Low:-23.97%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -13.13% |
| Q2 2025 | 11.85% |
| Q1 2025 | -4.17% |
| Q4 2024 | 8.12% |
| Q3 2024 | -1.72% |
| Q2 2024 | -12.97% |
| Q1 2024 | 9.89% |
| Q4 2023 | 7.36% |
| Q3 2023 | 13.13% |
| Q2 2023 | 3.50% |
| Q1 2023 | -1.27% |
| Q4 2022 | 17.11% |
| Q3 2022 | 24.13% |
| Q2 2022 | -13.31% |
| Q1 2022 | -0.67% |
| Q4 2021 | 1.17% |
| Q3 2021 | -10.17% |
| Q2 2021 | 6.71% |
| Q1 2021 | -2.33% |
| Q4 2020 | -7.69% |
| Q3 2020 | 43.90% |
| Q2 2020 | -20.23% |
| Q1 2020 | 0.48% |
| Q4 2019 | 7.93% |
| Q3 2019 | 18.02% |
| Q2 2019 | -23.97% |
| Q1 2019 | 18.45% |
| Q4 2018 | -0.17% |
| Q3 2018 | -6.72% |
| Q2 2018 | -21.21% |
| Q1 2018 | 33.45% |
| Q4 2017 | -5.67% |
| Q3 2017 | -2.51% |
| Q2 2017 | -6.97% |
| Q1 2017 | 0.52% |
| Q4 2016 | -3.03% |
| Q3 2016 | 6.83% |
| Q2 2016 | -22.92% |
| Q1 2016 | 16.59% |
| Q4 2015 | 20.78% |